Lipocine Stock Today
| LPCN Stock | USD 4.71 0.05 1.05% |
Performance8 of 100
| Odds Of DistressLess than 40
|
Lipocine is selling at 4.71 as of the 21st of November 2024; that is 1.05 percent decrease since the beginning of the trading day. The stock's open price was 4.76. Lipocine has about a 40 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Lipocine are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 22nd of October 2013 | Category Healthcare | Classification Health Care |
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The companys pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression LPCN 2101 for women with epilepsy, which has completed pre-clinical study and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company has 5.35 M outstanding shares of which 75.2 K shares are now shorted by private and institutional investors with about 2.8 trading days to cover. More on Lipocine
Moving together with Lipocine Stock
Moving against Lipocine Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Lipocine Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Mahesh Patel | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Management, Biotech, IT, Health Care, Pharmaceuticals, Biotechnology, Healthcare, Computing (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsLipocine can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lipocine's financial leverage. It provides some insight into what part of Lipocine's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Lipocine (LPCN) is traded on NASDAQ Exchange in USA. It is located in 675 Arapeen Drive, Salt Lake City, UT, United States, 84108 and employs 17 people. Lipocine is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 25.19 M. Lipocine conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 5.35 M outstanding shares of which 75.2 K shares are now shorted by private and institutional investors with about 2.8 trading days to cover.
Lipocine currently holds about 37.4 M in cash with (11.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.42.
Check Lipocine Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Lipocine is $25.19 Million. Roughly 87.14 % of Lipocine outstanding shares are held by general public with 2.91 pct. owned by insiders and only 9.95 % by institutional investors. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Lipocine Ownership Details
Lipocine Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Tower Research Capital Llc | 2024-06-30 | 772 | |
| Caldwell Sutter Capital Inc | 2024-09-30 | 471 | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 227 | |
| Hartland & Co | 2024-06-30 | 74.0 | |
| Tidemark Llc | 2024-09-30 | 59.0 | |
| Bank Of America Corp | 2024-06-30 | 44.0 | |
| Group One Trading, Lp | 2024-06-30 | 16.0 | |
| Royal Bank Of Canada | 2024-06-30 | 9.0 | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Vanguard Group Inc | 2024-09-30 | 221.5 K | |
| Blackrock Inc | 2024-06-30 | 89.3 K |
Lipocine Historical Income Statement
Lipocine Stock Against Markets
Lipocine Corporate Management
| CPA CPA | Co Sec | Profile | |
| Logan Morse | Marketing Sales | Profile | |
| Nachiappan Chidambaram | Senior Development | Profile | |
| M MD | Chief Director | Profile | |
| Krista Fogarty | Principal Controller | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.75) | Revenue Per Share 0.903 | Quarterly Revenue Growth 137.519 | Return On Assets (0.23) | Return On Equity (0.34) |
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.